STOCK TITAN

Medline Inc. announces launch of secondary offering of Class A common stock

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Medline (MDLN) announced that selling stockholders have launched an underwritten secondary offering of 60,000,000 shares of its Class A common stock. The sellers include affiliates of Blackstone, Carlyle and Hellman & Friedman, alongside GIC and its managed affiliate and an Abu Dhabi Investment Authority subsidiary. They intend to grant underwriters a 30-day option for up to 9,000,000 additional shares. Medline is selling no shares and will receive no proceeds.

Medline and Medline Holdings agreed to repurchase $200 million of Class A shares and limited partnership interests directly from the sellers at the price paid by underwriters. The repurchase is expected to close concurrently with, and depends on, the offering closing; the reverse condition does not apply. The offering registration statement is not yet effective.

Loading...
Loading translation...

Positive

  • Minor point$200 million repurchase agreed for Class A shares and partnership interests, counting toward Medline’s existing repurchase program.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.No offering proceeds will go to Medline; selling stockholders are selling all offered shares.
  • Minor pointRepurchase depends on the offering closing; the offering does not depend on the repurchase.
  • Minor pointRegistration statement is not yet effective; securities cannot be sold before effectiveness.

News Explained

If the agreed repurchase closes, then for every Medline Holdings limited partnership interest bought from a selling stockholder, that seller also transfers an equivalent number of Medline Class B shares to Medline for cancellation, with no additional consideration.

Key Figures

Shares offered: 60,000,000 shares Underwriters’ option: Up to 9,000,000 shares Repurchase: $200 million
Shares offered
60,000,000 shares
Secondary offering by selling stockholders
Underwriters’ option
Up to 9,000,000 shares
30-day option to purchase additional shares
Repurchase
$200 million
Agreed repurchase from selling stockholders at the offering price per equity interest

Previous Offering Reports

1 past event · Latest: May 20
Same Type 1 event
  1. May 20

    Secondary offering

    24h Move
    -3.9%

    A prior launch covered 60 million shares plus a 9 million-share option; the reported reaction was -3.85%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, registration statement, limited partnership interests
3 terms
underwritten public offering financial
"have commenced an underwritten public offering of 60,000,000 shares"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
registration statement regulatory
"pursuant to a registration statement filed with the Securities and Exchange Commission"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
limited partnership interests financial
"limited partnership interests of Medline Holdings"
An ownership stake in a limited partnership gives an investor the role of a limited partner who provides capital but does not run day-to-day operations; a separate general partner manages the business. It matters because limited partners share profits, losses, and tax benefits but generally cannot lose more than they invested and have little control or liquidity—think of it like quietly funding a small business while someone else manages it, with potential return and risk tied to the venture’s performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NORTHFIELD, Ill., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc. and Hellman & Friedman LLC along with GIC Private Limited and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority (collectively, the “Selling Stockholders”) have commenced an underwritten public offering of 60,000,000 shares of Medline’s Class A common stock (the “Offering”) pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Medline’s Class A common stock.

Medline is not selling any shares of Class A common stock in the Offering and will not receive any of the proceeds from the sale.

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers, and Blackstone Capital Markets and Carlyle are acting as co-managers for the proposed Offering.

The proposed Offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this Offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

In addition, Medline announced that it and Medline Holdings, LP (“Medline Holdings”) have agreed to repurchase an aggregate of $200 million of Medline’s Class A common stock and limited partnership interests of Medline Holdings (“Common Units”) directly from the Selling Stockholders in a private, non-underwritten transaction at a price per equity interest equal to the price paid by the underwriters in the Offering (the “Repurchase”). To the extent that Common Units are repurchased from a Selling Stockholder, upon closing of the Repurchase, such Selling Stockholder will also transfer an equivalent number of shares of Medline’s Class B common stock to Medline for no additional consideration, and such shares of Class B common stock will be cancelled and retired. The Repurchase is expected to close concurrently with the Offering and is conditioned upon the closing of the Offering. The closing of the Offering is not conditioned upon the closing of the Repurchase. The Repurchase has been approved by the Audit Committee of Medline’s Board of Directors and is pursuant to, and will count toward, Medline’s previously announced share repurchase program.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions, are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to Medline’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond Medline’s control, that could cause actual results to differ materially.

Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

Contacts:
Investor relations:
Karen King
Global Head, Investor Relations

Patrick Flaherty
Director, Investor Relations

+1.847.247.7222
IR@medline.com

Media relations:
Ben Fox
Vice President, Corporate Communications
+1.224.327.9999
media@medline.com

Source: Medline Inc.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares are being offered in Medline’s secondary offering?

Selling stockholders have launched an offering of 60,000,000 Class A shares and intend to grant underwriters a 30-day option to purchase up to 9,000,000 additional shares. Medline is not selling shares and will receive no sale proceeds.

What are the terms of Medline’s $200 million repurchase?

Medline and Medline Holdings agreed to repurchase an aggregate of $200 million of Class A shares and limited partnership interests directly from selling stockholders at the price paid by underwriters in the offering. The repurchase is expected to close concurrently with the offering and is conditional on its closing, but the offering can close without the repurchase.

What happens to Medline Class B shares when partnership interests are repurchased?

For any limited partnership interests repurchased, the selling stockholder will transfer an equivalent number of Class B shares to Medline for no additional consideration at the repurchase closing. Those Class B shares will be cancelled and retired.

Keep reading